Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, said: “The SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 ...

Despite the outcome, VE202 was well tolerated. Most adverse events were mild or moderate, with no reports of treatment-related serious adverse events. Further analyses on bacterial colonisation and ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Eli Lilly and Company and the UK Government have announced a joint programme to develop innovative models of care for obesity ...

Eli Lilly and Company has announced positive topline results from its phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) ...

Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children and adolescents aged 6–17 who weigh at least 45 kilograms.

Sever Pharma Solutions has deepened its partnership with Silo Pharma to advance a novel ketamine-based implant designed to ...

Celltrion has received US Food and Drug Administration approval for an expanded indication of AVTOZMA (tocilizumab-anoh) ...

Patients in Scotland with relapsed or refractory mantle cell lymphoma (MCL) after one line of treatment can now access ...

Everest Medicines has announced a strategic equity investment of US$30.9 million in I-Mab, acquiring 15,846,154 newly issued ...

Nxera Pharma has launched a broad proprietary pipeline focused on next-generation therapies for obesity and related metabolic ...

Porosome Therapeutics has announced major advances in Alzheimer’s disease research, including FDA validation of ...